Objective To explore the effect of sintilimab + sodium glycidiazole combined with radiotherapy in the treatment of locally advanced cervical cancer. Methods: Sixty patients with locally advanced cervical cancer admitted to our hospital from July 2023 to December 2024 were selected as the research subjects. The patients were divided into the control group and the observation group by random number table method, with 30 cases in each group. The control group was treated with cisplatin combined with paclitaxel chemotherapy and radiotherapy. The observation group received chemotherapy and radiotherapy with sintilimab combined with sodium glycidiazole. The clinical efficacy, adverse reactions, and tumor markers [squamous cell carcinoma antigen (SCC-Ag), cancer antigen 125 (CA125)] level and quality of life [36-Item Short Form Health Survey (SF-36 score)] of the two groups were analyzed and compared. Results: There was no significant difference in the objective response rate between the two groups (P > 0.05). The adverse reaction rate of the observation group was significantly lower than that of the control group (P < 0.05). After treatment, the levels of SCC-Ag and CA125 in both groups were significantly lower than those before treatment (P < 0.05). However, there was no significant difference in the levels of SCC-Ag and CA125 between the two groups after treatment (P > 0.05). After treatment, the SF-36 scores of both groups increased significantly compared with those before treatment, and the SF-36 score of the observation group after treatment was significantly higher than that of the control group (P < 0.05). Conclusion: Sintilimab combined with sodium glycidiazole chemotherapy and radiotherapy in the treatment of locally advanced cervical cancer has a good clinical efficacy, can improve safety and enhance the quality of life of patients.